2025-06-10-Jefferies-京东健康（6618）_线上到线下（O2O）业务启动与人工智能（AI）优势_目标价至60港元_10页_515kb

JD Health Summary

Core Content and Key Insights

JD Health is highlighted as a top pick in the Health IT sector, with a price target of HK$60, representing a +52% increase from its current price. The report outlines three main investment themes driving the valuation:

1. Branded Drug Business: JD Health is benefiting from a growing trend where customers are purchasing branded drugs directly through the platform, driven by concerns over the quality and efficacy of generic drugs. This shift is expected to increase traffic volume and diversify the customer base, with JDH acting as a commercialization partner for over 50 branded drugs. The 1P (self-operated) model is favored over the 3P (third-party) model for quality and supply stability.

2. O2O Market Share Gain: JD Health is expanding into the O2O (online-to-offline) space to compete with Meituan in the on-demand retail market. The company is building front warehouses for popular OTC products and leveraging its strong pharmaceutical supply chain and logistics capabilities, particularly in lower-tier cities. The company also benefits from favorable reimbursement policies in 18 cities, which support O2O drug purchases through public medical insurance. While there may be temporary margin pressures in FY25 and FY26 due to investment in the O2O model, the long-term market share gains are viewed as crucial for growth sustainability.

3. AI Monetization Opportunities: JD Health's LLM, Jingyi Qianxun, is noted as one of the top-performing healthcare-specific models in China. The AI is being used across 2C, 2B, and 2H scenarios, including smart health assistants, AI doctors, pharmacists, and nutritionists. These applications are expected to enhance user engagement and optimize ad placements, with revenue contributions from AI monetization anticipated from 2026 onwards.

Financial Projections

The price target of HK$60 is based on DCF methodology, with a WACC of 8.8% and a terminal growth rate of 3.0%. The report also outlines potential upside and downside scenarios:

• Upside Scenario: HK$90, +127% (faster user growth, higher Rx sales, and new service offerings)
• Downside Scenario: HK$20, -49% (slower growth, lower sales, and regulatory challenges)

Investment Thesis

The report's investment thesis is grounded in JD Health's ability to:

• Leverage its first-mover advantage in the online retail pharmacy space
• Expand into online and offline healthcare services
• Utilize its strong supply chain and logistics network
• Monetize AI-driven services for enhanced user engagement and ad placements
• Benefit from favorable reimbursement policies and regulatory support

Sustainability and ESG Targets

JD Health has set ambitious sustainability goals, including:

• Achieving a 50% reduction in logistics emissions by 2030 compared to 2019
• Working towards carbon neutrality by 2060

The report also raises questions to management regarding:

• Projected investments and savings in achieving ESG targets
• Systems in place to safeguard customer rights and data security

Key Catalysts

• Expansion of reimbursement policies to include B2C drug sales
• Launch of AI-driven services such as "Kangkang" and "Small Universe for Chatting and Healing"
• Open-sourcing of Jingyi Qianxun, the first fully open-source vertical model in the medical sector
• Integration of AI into online hospitals, with over 80% of consultations supported by AI

Risks and Considerations

• Competition: Intensifying competition from Meituan and others
• Regulatory Changes: Potential shifts in reimbursement policies or regulatory scrutiny
• Operational Risks: Challenges in scaling AI and O2O operations
• Financial Risks: Margin pressures from increased investment in new initiatives
• Currency Risk: For non-US investors, exchange rate fluctuations may impact target prices

Analysts and Disclosures

The report is authored by Cui Cui, David Shang, and Chu Wang, all Equity Analysts at Jefferies. It includes important disclosures regarding the potential for conflicts of interest, as Jefferies may engage in investment banking services with companies covered in the report. The report is not intended to be a personalized investment recommendation and should be considered as one of many factors in decision-making.

Other Companies Mentioned

• JD Health (6618 HK): Buy rating, PT HK$60
• Meituan (3690 HK): Buy rating, PT HK$185

Summary

JD Health is positioned as a strong investment opportunity due to its strategic expansion into branded drug sales, O2O healthcare services, and AI monetization. The company is expected to benefit from favorable reimbursement policies and its first-mover advantage in the online pharmacy space. While there are risks associated with increased investment and competition, the long-term growth potential is seen as substantial. The price target of HK$60 reflects a DCF-based valuation, with potential upside and downside scenarios outlined. The report emphasizes the importance of sustainability, ESG goals, and AI innovation in driving future growth.